타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Polatuzumab Vedotin |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development |
Positioning Known limitation | resistance to POLA in vivo |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD20 expression |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Polatuzumab Vedotin |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development |
Positioning Known limitation | resistance to POLA in vivo |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD20 expression |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교